Hemophagocytic Lymphohistiocytosis

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Hemophagocytic lymphohistiocytosis (HLH) is a rare, aggressive hyperinflammatory syndrome.
• It involves uncontrolled activation of lymphocytes and macrophages, leading to cytokine release and multi-organ damage.
• HLH presents in primary (genetic) and secondary (acquired) forms, often with overlapping clinical features, complicating diagnosis.

Purpose of the Study:

• To review the pathophysiology, clinical manifestations, diagnostic challenges, and therapeutic strategies for HLH.
• To highlight the complexities in differentiating primary and secondary HLH forms.
• To emphasize the critical need for timely and aggressive management.

Main Methods:

• Literature review of HLH pathophysiology, clinical presentation, and treatment modalities.
• Analysis of diagnostic criteria and challenges, including nonspecific symptoms.
• Evaluation of current and emerging therapeutic options, including immunosuppression, stem cell transplantation, and targeted therapies.

Main Results:

• HLH is characterized by uncontrolled immune activation, cytokine storm, and characteristic clinical and laboratory findings.
• Diagnostic challenges arise from nonspecific symptoms and the overlap between primary and secondary forms.
• Effective treatments include immunosuppressive therapy, hematopoietic stem cell transplantation for familial HLH, and targeted therapies like emapalumab.

Conclusions:

• HLH is a deadly disease requiring urgent immunosuppressive therapy to control hyperinflammation.
• Hematopoietic stem cell transplantation offers a curative option for familial HLH.
• Targeted therapies show promise in managing this complex hyperinflammatory condition.